WEBINAR PRESENTATION

2nd QUARTER 2019





2nd QUARTER





SALES IN 2nd QUARTER

Sales reached

EUR 31.7 million

An increase by

2%

compared to Q2 2018

Net sales by pharmacies


= EUR 6.2 million

Net sales by Silvanols

= EUR 0.9 million

Net sales by Tonus Elast and Elast Medical

= EUR 2.2 million





SALES IN 1st half of 2019 – new all-time record

Sales reached

EUR 66.4 million

An increase by

7%

compared to 1H 2018

Net sales by pharmacies


= EUR 12.6 million

Net sales by Silvanols

= EUR 2.1 million

Net sales by Tonus Elast and Elast Medical

= EUR 4.1 million





CONTINUING GROWTH OF EBITDA AND MARGIN


EBITDA in the 1st half of 2019 was **EUR 17 million** that grew by 64%

TTM EBITDA reached

EUR 26.8 million

TTM EBITDA margin further improved to 20.8%, from 19.8% last quarter

Group's TTM EBITDA and EBITDA margin





STRONG NET PROFIT IN THE 2ND QUARTER OF 2019

Net profit of EUR 4 million, which is an increase by 49% y-o-y

Highest 2nd quarter profit since 2014

Net profit for the 1st half of 2019 was

EUR 12.2 million, by far the largest in Group's history




FACTORS AFFECTING NET PROFIT

Main factor contributing to the increase of net profit:

- \$\mathbb{L}\$ Strong improvement in gross profit due to higher gross margin (61.9%, from 59.7%)
- ♣ Decline in marketing expenses (from 18.2 to 17 million EUR)
- ♣ Gains from favourable changes in Russian rouble rate (~2.7 million EUR)

Increase in administrative expenses from 11.4 to 13.6 million EUR negatively impacted net profit and was related to a rise in salaries and R&D expenses.



POLL QUESTION





SALES BY COUNTRIES, 1st half of 2019

Share of sales in TOP4 countries reached


77%

Latvia's share increased and Russia's share lost

1pp

- Share of sales in Ukraine decreased by 2pp and was 8% 1H, 2019
- The Netherlands are now the 5th largest market due to a renewed contract with the UN


SALES BREAKDOWN BY COUNTRIES, FIRST HALF OF 2019



GROWTH DRIVERS: COUNTRIES

- Most of major markets are growing
- Largest growth in monetary terms added by Latvia (EUR 2.2m), the Netherlands (EUR 1.6m) and Russia (EUR 0.7m)
- Largest growth in relative terms provided by the Netherlands (729%), Tajikistan (42%) and Uzbekistan (37%)
- Biggest loss in monetary terms comes from the **Ukraine** (EUR 0.6m) and **Lithuania** (-EUR 0.35 m)
- ♣ Biggest loss in relative terms is in Lithuania (-33%), the Ukraine (-9%) and Germany (-5%)


Sales to Top 10 countries, 1H 2019 vs 1H 2018



www.olainfarm.com

SALES BY PRODUCTS, 1st half of 2019

- Noofen's share rose by 1p.p. y-o-y and it remained **THE BESTSELLING PRODUCT**
- Neiromidin lost 1pp and Furamag/Furasol lost
 2pp but are still in TOP 3 product list
- PASS returned to the TOP 10 due to renewed supplies to the UN




*Final dosage forms only



GROWTH DRIVERS: PRODUCTS

- Out of the TOP 10 products nine are growing;
- The biggest growth in monetary terms added by PASS (1.6m), Noofen (0.8m) and Adaptol (0.5m);
- The biggest growth in relative terms provided by **PASS** (933%), **Remantadine** (121%) and **Furagin** (21%);

Bestselling Products, 1H 2019 vs 1H 2018, EUR '000



www.olainfarm.com

■ 1H 2019 ■ 1H 2018

POLL QUESTION





UPDATE ON RECENT EVENTS






BORROWINGS

- ABLV loan was refinanced by BlueOrange Bank:
 - Amount: 10.5 million EUR
 - Use of proceeds: refinancing and new investments
 - Duration: 5 years , full amortization
- Net Debt / EBITDA top limit is 2.3
- DSCR bottom limit is 1.5

Group's TTM EBITDA and EBITDA margin



MANAGEMENT REMUNERATION

Total remuneration including all taxes for all members of Supervisory Council and Management Board

Quarter	Amount, EUR	Changes, q-o-q, EUR	Changes, q-o-q, %	Comment
1Q 2018	264 474	-	-	
2Q 2018	317 633	53 159	20%	Supervisory Council election
3Q 2018	497 512	179 879	57%	Supervisory Council election
4Q 2018	704 811	207 299	42%	
1Q 2019	717 556	12 745	2%	
2Q 2019	616 994	-100 562	-14%	Supervisory Council election

NEED A CAR?

Start of a fully transparent process for the sale of luxury

vehicles:

- 3 BMW X5, BMW X5, BMW X1, BMW X4
- **MB** \$600, MB GLE 350
- Lexus NX 300

Total purchase cost was 386 thousand EUR



If interested please send a message olainfarm@olainfarm.com

POLL QUESTION






INVESTIGATION OF MARKETING EXPENSES

- Large-scale possibly fraudulent activity suspected in the use of the company's assets by former executives of JSC Olainfarm
- Marketing services raised doubts about their potential fictitious nature, economic validity and legitimacy
- The international auditor confirms that the transaction occurred, possibly causing losses to JSC Olainfarm
- Suspicious transactions occurred between 2 January, 2017 and 4 April, 2019
- Cooperation with the company has been completely suspended
- Criminal proceedings have been initiated by the police



NEW CEO

- Olainfarm is looking to hire a new Chairman of the Management Board with international experience in the pharmaceutical industry
- A recruitment company Amrop Latvia has been engaged
- The process is planned to be completed by the end of October
- Lauris Macijevskis, current Chairman of the Management Board, will continue to be a member of the Board of JSC Olainfarm



EGM ON NOVEMBER 1ST, 2019

- A request to convene an extraordinary general meeting of shareholders has been received from shareholder Ltd. "OLMAFARM":
 - Recall of the Council and Election of the new Council;
 - Recall of the Auditing committee and election of the new Auditing committee.
- Record date October 24th, 2019;
- Registration of shareholders will take place on the day of the meeting, i.e. November 1st, 2019, from 10:00 until 10:45 on the venue;
- Shareholder meeting starts at 11:00.

Q&A SESSION









Janis Dubrovskis

Investor Relations Advisor



(+371) 67 013 705



janis.dubrovskis@olainfarm.com



www.olainfarm.com



Rupnicu iela 5, Olaine, LV-2114, Latvia